Kimia Farma Tbk PT

Kimia Farma Tbk PT has a debt-to-equity ratio of 1.42, indicating a moderate reliance on debt financing, and a current ratio of 0.68, suggesting potential liquidity constraints. The company's negative operating cash flow of -112,917,231,000 IDR and free cash flow of -112,489,161,000 IDR highlight its cash flow challenges. The capital expenditure of -204,112,349,000 IDR reflects ongoing investment in infrastructure or operations. The company's profitability is underperforming, with a return on equity of -3.66% and a return on assets of -1.16%, both significantly below the industry median for Drug Retailers. The operating income of -136,102,607,000 IDR and net income of -195,052,487,000 IDR indicate a loss-making position, which is a concern for investors. Kimia Farma Tbk PT's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's exposure to the Indonesian market is high, and its performance is closely tied to domestic demand and regulatory conditions. The company's growth trajectory is negative, with a declining revenue trend and no clear signs of recovery in the near term. The operating income and net income have both turned negative, and the company is not showing signs of improving its financial performance. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The dilution risk is low, but the company's financial performance and cash flow issues could lead to future dilution if not addressed. Recent events, including the latest financial filings, show a continued decline in profitability and cash flow. The company's last actual EPS was -2.29 IDR, and the last actual revenue was 9,400,535,480,000 IDR, both indicating a challenging operating environment.